Boston Advisors’s Novartis NVS Stock Holding History

Boston Advisors’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$278K	Sell	3,194 -5,507	-63%	-$494K	0.01%	528
2019 Q2	$794K	Sell	8,701 -2,278	-21%	-$193K	0.04%	410
2019 Q1	$946K	Buy	10,979 +2	+0%	+$161	0.05%	353
2018 Q4	$844K	Sell	10,977 -1,480	-12%	-$115K	0.05%	348
2018 Q3	$962K	Buy	12,457 +2	+0%	+$148	0.04%	385
2018 Q2	$843K	Sell	12,455 -498	-4%	-$34.4K	0.02%	414
2018 Q1	$938K	Buy	12,953 +4,691	+57%	+$357K	0.02%	382
2017 Q4	$622K	Buy	8,262 +1,122	+16%	+$84.7K	0.01%	463
2017 Q3	$549K	Buy	7,140 +4,263	+148%	+$322K	0.01%	473
2017 Q2	$215K	Buy	+2,877	New	+$204K	0.01%	622
2016 Q1	–	Sell	-2,913	Closed	-$225K	–	679
2015 Q4	$225K	Buy	2,913 +221	+8%	+$17.6K	0.01%	617
2015 Q3	$222K	Hold	2,692	–	–	0.01%	719
2015 Q2	$237K	Buy	2,692 +269	+11%	+$24.7K	0.01%	626
2015 Q1	$214K	Sell	2,423 -254	-9%	-$22.5K	0.01%	630
2014 Q4	$222K	Buy	+2,677	New	+$222K	0.01%	550

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

Boston Advisors's NVS Position: Q3 2019 in Review

Boston Advisors reduced its Novartis (NVS) stake by 63% in Q3 2019, selling an estimated $494K and leaving 3,194 shares worth $278K. The position accounts for 0.01% of the portfolio, ranked #528.

Boston Advisors first reported a position in NVS in Q4 2014 and has held it in 15 quarters since. The position peaked at $962K in Q3 2018. 1,090 funds tracked by Wall St. Rank hold NVS as of Q3 2019.

Boston Advisors held 3,194 shares of Novartis worth $278K as of Q3 2019.
Boston Advisors sold 5,507 Novartis shares in Q3 2019, an estimated $494K.
Novartis made up 0.01% of Boston Advisors's portfolio in Q3 2019, its #528 holding.
Boston Advisors first reported a position in Novartis in Q4 2014 and has held it in 15 quarters since.
Boston Advisors's Novartis position peaked at $962K in Q3 2018.
1,090 funds tracked by Wall St. Rank held Novartis as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.